Outsourcing-Pharma.com presents its weekly round-up of the latest movers and shakers in the world of pharmaceuticals, including news from Chiltern, Thermo Fisher and Penn Pharma.
Production by Ireland’s pharmaceutical sector fell sharply in September but it is too early to say if it was part of a longer term decline, says the CSO
Barack Obama’s re-election will mean millions more US citizens have health insurance, which has significant implications for the pharmaceutical industry.
in-PharmaTechnologist.com presents its weekly round-up of the latest appointments in the pharmaceutical industry, including news from Watson, OvaScience and Sirona.
The positive impact drug industry demand for quality is having on the fine chemicals sector was evident at industry trade show CPhI last month according to expert Jan Ramakers.
Regulators in Non-EU countries can use results of previous inspections of API plants by EU or equivalent authorities in written confirmations, according to the European Commission.
New Zealand regulator Medsafe and the Taiwan FDA will join the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) next year.
Lonza says it will cut jobs at its facility in Visp, Switzerland and that it may enact ‘similar productivity improvement programmes’ at other facilities.
The full impact of Superstorm Sandy is still being assessed, but early reports suggest that the East coast contract manufacturing industry has escaped relatively unscathed.
Pharmaceutical firms should let the EMA know about minor variations to marketing authorisation (MA) by the end of next month if they want to avoid delays over the festive period.
Outsourcing-pharma.com presents a roundup of contract manufacturing news with deals for Lonza, DSM and Ark Therapeutics and an expanded agreement with Shire for AMRI.
The UK Intellectual Property Office (IPO) wants to make it easier to develop drugs in the country by changing the rules relating to patent infringement in clinical trials.
Discovery of the genetic basis for the placebo effect in IBS patients has wider implications for protocol design and trials of personalised medicines say researchers.
in-PharmaTechnologist.com presents its weekly round-up of career changes in the pharmaceutical industry, including news from Heptares, Cerecor and Dyax Corp.
